Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer

Olaparib combined with chemotherapy enhances short- and long-term efficacy, improves immune function, and prolongs survival in advanced TNBC without increasing treatment-related toxicity, supporting its clinical utility.

Authors

Wanfu Wang

Institutions

Shanxi Provincial Cancer Hospital (CN)

Publication Details

Journal: American Journal of Cancer Research
Published: 2025-01-01
DOI: https://doi.org/10.62347/gcge6470
Primary Topic: PARP inhibition in cancer therapy
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer

Wanfu Wang

Jan 1, 2025

American Journal of Cancer Research

PARP inhibition in cancer therapy

article

Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer

Wanfu Wang

January 1, 2025article en

Abstract

American Journal of Cancer ResearchVol. 15(7)

Shanxi Provincial Cancer Hospital (CN)

Good health and well-being

Openalex Percentile: Top 73%

PARP inhibition in cancer therapy

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer — Wanfu Wang · American Journal of Cancer Research (2025) | TGRS Research Map | TGRS